[
  {
    "ts": "2025-07-10T15:14:14+00:00",
    "headline": "RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while […]",
    "url": "https://finance.yahoo.com/news/rbc-capital-maintains-buy-biogen-151414761.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "dcdaf275-36d8-3a32-b73a-9b5bbf1385bc",
      "content": {
        "id": "dcdaf275-36d8-3a32-b73a-9b5bbf1385bc",
        "contentType": "STORY",
        "title": "RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while […]",
        "pubDate": "2025-07-10T15:14:14Z",
        "displayTime": "2025-07-10T15:14:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-maintains-buy-biogen-151414761.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-maintains-buy-biogen-151414761.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-10T11:00:00+00:00",
    "headline": "Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
    "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., July 10, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a bro",
    "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-announce-presentation-110000381.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "111fad67-cf61-3941-9de2-87db3c707efe",
      "content": {
        "id": "111fad67-cf61-3941-9de2-87db3c707efe",
        "contentType": "STORY",
        "title": "Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
        "description": "",
        "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., July 10, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a bro",
        "pubDate": "2025-07-10T11:00:00Z",
        "displayTime": "2025-07-10T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/1a397dbb9e9532f7932ff4032e4a0488",
          "originalWidth": 480,
          "originalHeight": 223,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h8PBqD4_hn0rzbf825eYNg--~B/aD0yMjM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a397dbb9e9532f7932ff4032e4a0488.cf.webp",
              "width": 480,
              "height": 223,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bt8g56SHkvgge7Nr16QCrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a397dbb9e9532f7932ff4032e4a0488.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-announce-presentation-110000381.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-announce-presentation-110000381.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "STOK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-10T11:00:00+00:00",
    "headline": "Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
    "summary": "– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK)",
    "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-announce-presentation-110000227.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d63bafbb-dece-3a21-a3fb-fbd1e9df290d",
      "content": {
        "id": "d63bafbb-dece-3a21-a3fb-fbd1e9df290d",
        "contentType": "STORY",
        "title": "Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress",
        "description": "",
        "summary": "– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK)",
        "pubDate": "2025-07-10T11:00:00Z",
        "displayTime": "2025-07-10T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-announce-presentation-110000227.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-announce-presentation-110000227.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STOK"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-10T04:39:53+00:00",
    "headline": "Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT",
    "summary": "Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded the company’s stock to “Overweight” from “Equal Weight” with a price objective of $57, an increase from the prior target of $51, ahead of the Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia, as reported by The […]",
    "url": "https://finance.yahoo.com/news/barclays-upgrades-ionis-pharmaceuticals-ions-043953898.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b70311f1-a8b1-31e1-abaa-362e69a3499d",
      "content": {
        "id": "b70311f1-a8b1-31e1-abaa-362e69a3499d",
        "contentType": "STORY",
        "title": "Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT",
        "description": "",
        "summary": "Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded the company’s stock to “Overweight” from “Equal Weight” with a price objective of $57, an increase from the prior target of $51, ahead of the Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia, as reported by The […]",
        "pubDate": "2025-07-10T04:39:53Z",
        "displayTime": "2025-07-10T04:39:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8379a36660335f81d941e9aea3a89899",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSYTQTBooWDoBKwW7ESEVQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8379a36660335f81d941e9aea3a89899.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q4.76VCpmoEjEjoogiD0eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8379a36660335f81d941e9aea3a89899.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-upgrades-ionis-pharmaceuticals-ions-043953898.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-upgrades-ionis-pharmaceuticals-ions-043953898.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IONS"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]